# reload+after+2024-01-21 19:46:09.943720
address1§Gooimeer 2-35
city§Naarden
zip§1411 DC
country§Netherlands
phone§31 35 206 2971
website§https://www.newamsterdampharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
fullTimeEmployees§22
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Michael Harvey Davidson FACC, Facp., M.D.', 'age': 66, 'title': 'CEO, President, Executive Board Member & Director', 'yearBorn': 1957, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.', 'age': 69, 'title': 'Founder, Chief Scientific Officer, Member of Executive Board & Director', 'yearBorn': 1954, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mayur Amrat Somaiya', 'age': 50, 'title': 'Chief Financial Officer', 'yearBorn': 1973, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Douglas F. Kling', 'age': 50, 'title': 'Chief Operating Officer', 'yearBorn': 1973, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jim  Jacobson', 'title': 'Chief Legal Officer & Secretary', 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Marc  Ditmarsch M.D.', 'age': 56, 'title': 'Chief Development Officer', 'yearBorn': 1967, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lina  Gugucheva', 'age': 36, 'title': 'Chief Business Officer', 'yearBorn': 1987, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Sheng  Cui Ph.D.', 'title': 'VP & Head of Chemistry Manufacturing and Controls (CMC)', 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Annie  Neild', 'title': 'VP & Head of Regulatory Affairs', 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. William  Jones Jr., M.B.A.', 'age': 59, 'title': 'Chief Commercial Officer', 'yearBorn': 1964, 'exercisedValue': 0, 'unexercisedValue': 0}]
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§-0.09
priceToSalesTrailing12Months§76.636505
currency§USD
dateShortInterest§1702598400
forwardEps§-2.11
exchange§NGM
quoteType§EQUITY
shortName§NewAmsterdam Pharma Company N.V
longName§NewAmsterdam Pharma Company N.V.
firstTradeDateEpochUtc§1612881000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§eaa26311-e3c9-331e-9693-8ad0dbaf89e6
gmtOffSetMilliseconds§-18000000
targetHighPrice§28.09
targetLowPrice§24.08
targetMeanPrice§25.83
targetMedianPrice§25.58
recommendationMean§1.2
recommendationKey§strong_buy
numberOfAnalystOpinions§4
quickRatio§10.004
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
